Theranostics for Triple-Negative Breast Cancer

被引：17

作者：

Choi, Hyeryeon ^{[1
]}

Kim, Kwangsoon ^{[2
]}

机构：

[1] Eulji Univ, Eulji Med Ctr, Dept Surg, Sch Med, Seoul 01830, South Korea

[2] Catholic Univ Korea, Coll Med, Dept Surg, Seoul 06591, South Korea

来源：

DIAGNOSTICS | 2023年 / 13卷 / 02期

关键词：

theranostics; nanomedicine; immunotherapy; breast cancer; PEMBROLIZUMAB PLUS CHEMOTHERAPY; GAMMA-SECRETASE INHIBITORS; POLYMERIC MICELLES; CARBON NANOTUBES; DOUBLE-BLIND; ANTITUMOR-ACTIVITY; QUANTUM DOTS; DRUG; DELIVERY; CELLS;

D O I：

10.3390/diagnostics13020272

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with poor prognosis. Current endocrine therapy or anti HER-2 therapy is not available for these patients. Chemotherapeutic treatment response varies among patients due to the disease heterogeneity. To overcome these challenges, theranostics for treating TNBC have been widely investigated. Anticancer material conjugated nanoparticles with target-binding ligand and tracer agents enable simultaneous drug delivery and visualization of the lesion with minimal off-target toxicity. In this review, we summarize recently FDA-approved targeted therapies for TNBC, such as poly-ADP-ribose polymerase (PARP) inhibitors, check point inhibitors, and antibody-drug conjugates. Particularly, novel theranostic approaches including lipid-based, polymer-based, and carbon-based nanocarriers are discussed, which can provide basic overview of nano-therapeutic modalities in TNBC diagnosis and treatment.

引用

页数：13

共 101 条

[1]

Adams S, 2019, ANN ONCOL, V30, P405, DOI [10.1093/annonc/mdy518, 10.1093/annonc/mdy517]

[2] Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up A Phase 1b Clinical Trial [J].

Adams, Sylvia ;

Diamond, Jennifer R. ;

Hamilton, Erika ;

Pohlmann, Paula R. ;

Tolaney, Sara M. ;

Chang, Ching-Wei ;

Zhang, Wei ;

Iizuka, Koho ;

Foster, Paul G. ;

Molinero, Luciana ;

Funke, Roel ;

Powderly, John .

JAMA ONCOLOGY, 2019, 5 (03) :334-342

[3] Liposome: classification, preparation, and applications [J].

Akbarzadeh, Abolfazl ;

Rezaei-Sadabady, Rogaie ;

Davaran, Soodabeh ;

Joo, Sang Woo ;

Zarghami, Nosratollah ;

Hanifehpour, Younes ;

Samiei, Mohammad ;

Kouhi, Mohammad ;

Nejati-Koshki, Kazem .

NANOSCALE RESEARCH LETTERS, 2013, 8

[4] Differential metabolic responses to pluronic in MDR and non-MDR cells: A novel pathway for chemosensitization of drug resistant cancers [J].

Alakhova, Daria Yu. ;

Rapoport, Nataliya Y. ;

Batrakova, Elena V. ;

Timoshin, Alexander A. ;

Li, Shu ;

Nicholls, David ;

Alakhov, Valery Yu. ;

Kabanov, Alexander V. .

JOURNAL OF CONTROLLED RELEASE, 2010, 142 (01) :89-100

[5] The use of nanocrystals in biological detection [J].

Alivisatos, P .

NATURE BIOTECHNOLOGY, 2004, 22 (01) :47-52

[6] Lipid Nanocarriers of a Lipid-Conjugated Estrogenic Derivative Inhibit Tumor Growth and Enhance Cisplatin Activity against Triple-Negative Breast Cancer: Pharmacokinetic and Efficacy Evaluation [J].

Andey, Terrick ;

Sudhakar, Godeshala ;

Marepally, Srujan ;

Patel, Apurva ;

Banerjee, Rajkumar ;

Singh, Mandip .

MOLECULAR PHARMACEUTICS, 2015, 12 (04) :1105-1120

[7] Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival [J].

Auvinen, P ;

Tammi, R ;

Parkkinen, J ;

Tammi, M ;

Ågren, U ;

Johansson, R ;

Hirvikoski, P ;

Eskelinen, M ;

Kosma, VM .

AMERICAN JOURNAL OF PATHOLOGY, 2000, 156 (02) :529-536

[8] Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer [J].

Bardia, A. ;

Hurvitz, S. A. ;

Tolaney, S. M. ;

Loirat, D. ;

Punie, K. ;

Oliveira, M. ;

Brufsky, A. ;

Sardesai, S. D. ;

Kalinsky, K. ;

Zelnak, A. B. ;

Weaver, R. ;

Traina, T. ;

Dalenc, F. ;

Aftimos, P. ;

Lynce, F. ;

Diab, S. ;

Cortes, J. ;

O'Shaughnessy, J. ;

Dieras, V ;

Ferrario, C. ;

Schmid, P. ;

Carey, L. A. ;

Gianni, L. ;

Piccart, M. J. ;

Loibl, S. ;

Goldenberg, D. M. ;

Hong, Q. ;

Olivo, M. S. ;

Itri, L. M. ;

Rugo, H. S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16) :1529-1541

[9] Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer [J].

Bardia, Aditya ;

Mayer, Ingrid A. ;

Diamond, Jennifer R. ;

Moroose, Rebecca L. ;

Isakoff, Steven J. ;

Starodub, Alexander N. ;

Shah, Nikita C. ;

O'Shaughnessy, Joyce ;

Kalinsky, Kevin ;

Guarino, Michael ;

Abramson, Vandana ;

Juric, Dejan ;

Tolaney, Sara M. ;

Berlin, Jordan ;

Messersmith, Wells A. ;

Ocean, Allyson J. ;

Wegener, William A. ;

Maliakal, Pius ;

Sharkey, Robert M. ;

Govindan, Serengulam V. ;

Goldenberg, David M. ;

Vahdat, Linda T. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) :2141-+

[10] Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome [J].

Beckers, Rhiannon K. ;

Selinger, Christina I. ;

Vilain, Ricardo ;

Madore, Jason ;

Wilmott, James S. ;

Harvey, Kate ;

Holliday, Anne ;

Cooper, Caroline L. ;

Robbins, Elizabeth ;

Gillett, David ;

Kennedy, Catherine W. ;

Gluch, Laurence ;

Carmalt, Hugh ;

Mak, Cindy ;

Warrier, Sanjay ;

Gee, Harriet E. ;

Chan, Charles ;

McLean, Anna ;

Walker, Emily ;

McNeil, Catriona M. ;

Beith, Jane M. ;

Swarbrick, Alexander ;

Scolyer, Richard A. ;

O'Toole, Sandra A. .

HISTOPATHOLOGY, 2016, 69 (01) :25-34

← 1 2 3 4 5 6 7 8 9 10 →